Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Salinomycin nanoparticle - Tharimmune

Next Previous
Drug Profile

Salinomycin nanoparticle - Tharimmune

Alternative Names: HSB-1216

Latest Information Update: 28 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hillstream BioPharma
  • Developer Dana-Farber Cancer Institute; Indian Institutes of Technology; Tharimmune
  • Class Antibacterials; Antineoplastics; Antiprotozoals; Butyric acids; Polyketides; Small molecules
  • Mechanism of Action Apoprotein stimulants; Apoptosis stimulants; Ferroptosis stimulants; Neoplastic stem cell inhibitors; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer; Uveal melanoma
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Carcinoma; Triple negative breast cancer
  • Preclinical Acute myeloid leukaemia; Non-small cell lung cancer
  • No development reported Small cell lung cancer

Most Recent Events

  • 28 Jun 2024 No recent reports of development identified for preclinical development in Triple-negative-breast-cancer in USA (Intratumoural, Injection)
  • 28 Oct 2023 No recent reports of development identified for preclinical development in Small-cell-lung-cancer in USA (Intratumoural, Injection)
  • 27 Apr 2023 Hillstream Biopharma plans a clinical trial for Cancer in second half of 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top